Millennium Management’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $21.8M | Sell |
28,200
-10,800
| -28% | -$8.27M | 0.01% | 1477 |
|
|
2025
Q4 | $30.1M | Buy |
39,000
+27,700
| +245% | +$18.8M | 0.01% | 1186 |
|
|
2025
Q3 | $6.35M | Sell |
11,300
-54,100
| -83% | -$30.6M | ﹤0.01% | 2882 |
|
|
2025
Q2 | $34.3M | Buy |
65,400
+23,000
| +54% | +$12.8M | 0.02% | 1080 |
|
|
2025
Q1 | $26.9M | Buy |
42,400
+16,300
| +62% | +$11.2M | 0.01% | 1238 |
|
|
2024
Q4 | $18.6M | Buy |
26,100
+14,600
| +127% | +$12.3M | 0.01% | 1578 |
|
|
2024
Q3 | $12.1M | Sell |
11,500
-31,200
| -73% | -$34.7M | 0.01% | 2019 |
|
|
2024
Q2 | $44.9M | Sell |
42,700
-18,100
| -30% | -$17.5M | 0.02% | 875 |
|
|
2024
Q1 | $58.5M | Sell |
60,800
-14,200
| -19% | -$13.5M | 0.03% | 727 |
|
|
2023
Q4 | $65.9M | Buy |
75,000
+13,300
| +22% | +$11M | 0.03% | 632 |
|
|
2023
Q3 | $50.8M | Sell |
61,700
-14,300
| -19% | -$11.2M | 0.03% | 697 |
|
|
2023
Q2 | $54.6M | Buy |
76,000
+69,800
| +1,126% | +$53.8M | 0.03% | 673 |
|
|
2023
Q1 | $5.09M | Sell |
6,200
-27,500
| -82% | -$20.7M | ﹤0.01% | 2593 |
|
|
2022
Q4 | $24.3M | Buy |
33,700
+500
| +2% | +$369K | 0.01% | 1277 |
|
|
2022
Q3 | $22.9M | Buy |
33,200
+12,000
| +57% | +$7.55M | 0.01% | 1229 |
|
|
2022
Q2 | $12.5M | Sell |
21,200
-300
| -1% | -$195K | 0.01% | 1766 |
|
|
2022
Q1 | $15M | Sell |
21,500
-5,800
| -21% | -$3.67M | 0.01% | 1683 |
|
|
2021
Q4 | $17.2M | Sell |
27,300
-11,900
| -30% | -$7.32M | 0.01% | 1583 |
|
|
2021
Q3 | $23.7M | Sell |
39,200
-28,800
| -42% | -$17.9M | 0.01% | 1166 |
|
|
2021
Q2 | $38M | Buy |
68,000
+35,500
| +109% | +$18M | 0.02% | 752 |
|
|
2021
Q1 | $15.4M | Sell |
32,500
-18,000
| -36% | -$8.76M | 0.01% | 1336 |
|
|
2020
Q4 | $24.4M | Buy |
50,500
+30,500
| +153% | +$16.5M | 0.02% | 913 |
|
|
2020
Q3 | $11.2K | Buy |
20,000
+5,000
| +33% | +$3.03M | 0.01% | 1160 |
|
|
2020
Q2 | $9.36M | Buy |
+15,000
| New | +$8.51M | 0.01% | 1259 |
|
|
2019
Q4 | – | Sell |
-30,000
| Closed | -$8.32M | – | 4565 |
|
|
2019
Q3 | $8.32M | Sell |
30,000
-30,000
| -50% | -$8.88M | 0.01% | 1412 |
|
|
2019
Q2 | $18.8M | Buy |
+60,000
| New | +$20M | 0.03% | 834 |
|
|
2017
Q3 | – | Sell |
-25,000
| Closed | -$12.3M | – | 3805 |
|
|
2017
Q2 | $12.3M | Hold |
25,000
| – | – | 0.02% | 939 |
|
|
2017
Q1 | $9.69M | Buy |
+25,000
| New | +$9.27M | 0.02% | 1050 |
|
|
2014
Q1 | – | Sell |
-1,000
| Closed | -$275K | – | 3813 |
|
|
2013
Q4 | $275K | Sell |
1,000
-2,200
| -69% | -$633K | ﹤0.01% | 3100 |
|
|
2013
Q3 | $1M | Buy |
+3,200
| New | +$842K | ﹤0.01% | 2108 |
|
Other funds holding REGN
VCM
N
Millennium Management's REGN Position: Q1 2026 in Review
Millennium Management reduced its Regeneron Pharmaceuticals (REGN) stake by 83% in Q1 2026, selling an estimated $243M and leaving 62,730 shares worth $48.5M. The position accounts for 0.02% of the portfolio, ranked #848.
Millennium Management first reported a position in REGN in Q2 2013 and has held it in 51 quarters since. The position peaked at $293M in Q4 2025. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Millennium Management held 62,730 shares of Regeneron Pharmaceuticals worth $48.5M as of Q1 2026.
- Millennium Management sold 317,038 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $243M.
- Regeneron Pharmaceuticals made up 0.02% of Millennium Management's portfolio in Q1 2026, its #848 holding.
- Millennium Management first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 51 quarters since.
- Millennium Management's Regeneron Pharmaceuticals position peaked at $293M in Q4 2025.
- 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.